Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nephros Inc. (NEPH : NSDQ)
 
 • Company Description   
Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider.

Number of Employees: 34

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.98 Daily Weekly Monthly
20 Day Moving Average: 104,195 shares
Shares Outstanding: 10.32 (millions)
Market Capitalization: $20.43 (millions)
Beta: 1.23
52 Week High: $11.67
52 Week Low: $1.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -56.48% -52.51%
12 Week -54.48% -52.08%
Year To Date -66.44% -60.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
380 LACKAWANNA PLACE
-
SOUTH ORANGE,NJ 07079
USA
ph: 201-343-5202
fax: 201-343-5207
ksmith@pcgadvisory.com http://www.nephros.com
 
 • General Corporate Information   
Officers
Andrew Astor - Chief Executive Officer; President and Chief Finan
Arthur H. Amron - Director
Oliver Spandow - Director
Alisa Lask - Director
Thomas Gwydir - Director

Peer Information
Nephros Inc. (BJCT)
Nephros Inc. (CADMQ)
Nephros Inc. (APNO)
Nephros Inc. (UPDC)
Nephros Inc. (IMTIQ)
Nephros Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 640671400
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 10.32
Most Recent Split Date: 7.00 (0.11:1)
Beta: 1.23
Market Capitalization: $20.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.58 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.52
Price/Cash Flow: -
Price / Sales: 2.07
EPS Growth
vs. Year Ago Period: -233.33%
vs. Previous Quarter: -81.82%
Sales Growth
vs. Year Ago Period: -20.07%
vs. Previous Quarter: -20.90%
ROE
03/31/22 - -36.24
12/31/21 - -25.91
09/30/21 - -24.12
ROA
03/31/22 - -30.71
12/31/21 - -22.00
09/30/21 - -20.50
Current Ratio
03/31/22 - 6.67
12/31/21 - 5.70
09/30/21 - 7.47
Quick Ratio
03/31/22 - 3.99
12/31/21 - 3.70
09/30/21 - 4.92
Operating Margin
03/31/22 - -53.75
12/31/21 - -37.74
09/30/21 - -37.14
Net Margin
03/31/22 - -53.75
12/31/21 - -37.74
09/30/21 - -37.14
Pre-Tax Margin
03/31/22 - -53.75
12/31/21 - -37.17
09/30/21 - -35.94
Book Value
03/31/22 - 1.30
12/31/21 - 1.44
09/30/21 - 1.50
Inventory Turnover
03/31/22 - 0.97
12/31/21 - 0.97
09/30/21 - 0.89
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.01
09/30/21 - 0.01
Debt-to-Capital
03/31/22 - 0.18
12/31/21 - 0.64
09/30/21 - 1.06
 

Powered by Zacks Investment Research ©